RespireRx Pharmaceuticals, Inc. (RSPI)

OTCMKTS: RSPI · Delayed Price · USD
0.0084
-0.0004 (-4.55%)
Sep 30, 2022 4:00 PM EDT - Market closed
-4.55%
Market Cap 1.00M
Revenue (ttm) n/a
Net Income (ttm) -3.17M
Shares Out 119.59M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,000
Open 0.0084
Previous Close 0.0088
Day's Range 0.0084 - 0.0084
52-Week Range 0.0031 - 0.0330
Beta 0.15
Analysts n/a
Price Target n/a
Earnings Date n/a

About RSPI

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program... [Read more...]

Industry Pharmaceuticals
Founded 1987
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol RSPI
Full Company Profile

Financial Performance

Financial Statements

News

RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep A...

Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tr...

1 month ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by Cu...

Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tre...

4 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAki...

Glen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tr...

4 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compoun...

Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary t...

6 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures an...

Glen Rock, N.J., March 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary t...

6 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmac...

Glen Rock, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tr...

8 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™

Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to discover and develop innovative and revolutionary treatm...

9 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Developm...

Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary ...

9 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81

Glen Rock, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary ...

10 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Tr...

Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary...

10 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces CEO's OTC Venture Market Podcast

Glen Rock, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and revolutionary ...

10 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO

Glen Rock, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and revolutionary ...

10 months ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference

Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolut...

1 year ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal C...

Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary t...

1 year ago - GlobeNewsWire

RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs

Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary...

1 year ago - GlobeNewsWire

Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI

Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the OTC...

1 year ago - GlobeNewsWire